Indeed, blocking antibodies against PD-1 (such as Nivolumab and Pembrolizumab) and against PD-L1 (such as Atezolizumab) have been approved by the US Food and Drug Administration (FDA) for melanoma, non-small-cell lung cancers and MSI tumors (8). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.